Summary
This 8-K filing by Schering-Plough Corporation, on behalf of the Merck/Schering-Plough Pharmaceuticals joint venture, announces a significant regulatory milestone: the marketing approval of EZETROL(TM) (ezetimibe) 10 mg tablets in Germany. This approval allows for its use as a monotherapy and in combination with all marketed statins for the treatment of elevated cholesterol levels. This marks the initial step in the joint venture's strategy to gain marketing authorization across the European Union. Investors should note that the U.S. Food and Drug Administration (FDA) is currently reviewing the New Drug Application (NDA) for ezetimibe, which will be marketed as ZETIA(TM) in the United States. The approval in Germany and the ongoing FDA review represent key developments for the Merck/Schering-Plough Pharmaceuticals joint venture, potentially broadening the treatment options for hypercholesterolemia patients and driving future revenue growth for both parent companies.
Key Highlights
- 1Merck/Schering-Plough Pharmaceuticals joint venture received marketing approval for EZETROL(TM) (ezetimibe) in Germany on October 17, 2002.
- 2EZETROL(TM) is approved for use alone and in combination with all marketed statins for elevated cholesterol.
- 3This German approval is the first step towards seeking marketing authorization throughout the European Union.
- 4The U.S. New Drug Application (NDA) for ezetimibe (to be marketed as ZETIA(TM) in the US) was submitted to the FDA on December 27, 2001, and is currently under review.
- 5This development signifies a potential new product launch for the joint venture in major markets.
- 6The filing also references underlying agreements governing the joint venture: the Cholesterol Governance Agreement and the Master Agreement.